Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Pro Medicus Limited ( (AU:PME) ) just unveiled an update.
Pro Medicus Limited has announced an update on its ongoing share buy-back program, with a total of 1,060 ordinary fully paid securities bought back on the previous day, adding to the 42,164 securities bought back prior. This buy-back initiative is part of the company’s strategy to optimize its capital structure and potentially increase shareholder value, reflecting a proactive approach to managing its financial resources.
The most recent analyst rating on (AU:PME) stock is a Buy with a A$350.00 price target. To see the full list of analyst forecasts on Pro Medicus Limited stock, see the AU:PME Stock Forecast page.
More about Pro Medicus Limited
Pro Medicus Limited operates in the healthcare technology industry, providing advanced imaging software and services primarily for the medical sector. The company focuses on delivering innovative solutions to enhance medical imaging and streamline healthcare operations.
YTD Price Performance: -6.09%
Average Trading Volume: 175,864
Technical Sentiment Signal: Buy
Current Market Cap: A$24.5B
See more data about PME stock on TipRanks’ Stock Analysis page.